Courtney J. Wessel was promoted to Engagement Strategy Supervisor at AbelsonTaylor, an award-winning health and wellness advertising agency. Wessel joined AbelsonTaylor 18 months ago as a Senior Engagement Strategist and recently helped launch G1 Therapeutics’ COSELA™ (trilaciclib), the first and only FDA-approved therapy indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients living with extensive-stage small cell lung cancer (ES-SCLC)